ArticleslgStudy

science

Siltuximab

Siltuximab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Siltuximab rather than just read about it. In short: Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6.

Key takeaways

  • Siltuximab belongs to science; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Siltuximab to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Siltuximab from memory before moving on to harder problems.

Reference excerpt

Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist. The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. In April 2014, siltuximab was approved for medical use in the United States for the treatment of people with multicentric Castleman's disease who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8).

Medical uses Siltuximab is indicated for the treatment of people with multicentric Castleman's disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Side effects The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.

Drug interactions Siltuximab may increase CYP450 activity leading to increased metabolism of drugs that are CYP450 substrates.

Mechanism of action Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors. Siltuximab interferes with IL-6 mediated growth of B-lymphocytes and plasma cells, secretion of vascular endothelial growth factor (VEGF) and autoimmune phenomena.

History Siltuximab demonstrated efficacy and safety in people with idiopathic multicentric Castleman disease, found research formally published in 2016. Treatment results with siltuximab in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease. The approval by the US FDA was based on an international, multicenter, randomized (2:1), phase II study comparing every three-week intravenous infusions of siltuximab and best supportive care to placebo and best supportive care. The trial enrolled 79 participants and randomly allocated 53 participants to the siltuximab arm plus best supportive care and 26 participants randomized to the placebo arm plus best supportive care. Siltuximab was administered every three weeks as an intravenous infusion at a dose of 11 mg/kg.

Research Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castleman's disease. Siltuximab has been evaluated in the treatment of ovarian cancer, however the efficacy for this cancer is debatable. In addition, siltuximab has been evaluated for multiple myeloma, but there was an insignificant increase in response rates.

References

Worked examples

Example 1 — a first encounter with Siltuximab

Start with the simplest possible case. Write down what Siltuximab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Siltuximab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Siltuximab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Siltuximab

In research
Siltuximab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Siltuximab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Siltuximab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life
Look for Siltuximab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Siltuximab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Siltuximab in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Siltuximab means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Siltuximab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Siltuximab in simple terms?

Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6.

Why does Siltuximab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Siltuximab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Siltuximab.

Tags

  • Monoclonal antibodies
  • Orphan drugs

Keep exploring